A safety and efficacy of oral itraconazole and oral itraconazole with isotretinoin in chronic and recurrent dermatophytosis- A randomized trial
- 1Senior Resident, Department of Dermatology, Venereology and Leprology, Bhagat Phool Singh Government Medical College for Women, Sonepat, Haryana, India
- 2Associate Professor, Department of Dermatology, Venereology and Leprology, Bhagat Phool Singh Government Medical College for Women, Sonepat, Haryana, India
- 3Professor and Head, Department of Dermatology, Venereology and Leprology, Bhagat Phool Singh Government Medical College for Women, Sonepat, Haryana, India
Abstract
Background: A significant rise in chronic and recalcitrant dermatophytosis unresponsive to standard antifungals at recommended doses and durations has been observed in recent years. This growing resistance underscores the need for newer adjuvant therapies, such as combining isotretinoin with itraconazole. Aims and Objectives: The aim of the study was to evaluate the safety and efficacy of oral itraconazole versus itraconazole with isotretinoin in chronic and recurrent dermatophytosis. Materials and Methods: Patients were randomized into two groups. Group A received itraconazole 200 mg orally daily for 4 weeks, while Group B received itraconazole plus isotretinoin 20 mg daily. Results: Of 70 patients enrolled, 64 (33 in Group A, 31 in Group B) completed the study. Group B demonstrated a significant reduction in Clinical Assessment Score at 4 weeks (P=0.007). Excellent (>80%) improvement in Global Assessment Index was achieved in 58% of Group A and 78% of Group B (P=0.011). Patient satisfaction was higher in Group B (83.8%) compared to Group A (57.5%) (P=0.03). Mycological cure on potassium hydroxide was obtained in 63.6% of Group A and 90.3% of Group B (P=0.012). Relapse rates at 2month follow up were significantly lower in Group B (P=0.014). Conclusion: The combination of oral isotretinoin and itraconazole was more effective than itraconazole monotherapy in achieving clinical and mycological cure, improving patient satisfaction, and reducing relapse in chronic, recurrent dermatophytosis.
Related
- Comparative Efficacy of Vancomycin and Fidaxomicin Regimens for the Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
- Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy ± bevacizumab for recurrent or metastatic cervical cancer: a systematic review and meta-analysis of randomized controlled trials
- Evaluation of Clinicians’ Knowledge of Terbinafine-resistant Extensive Dermatophytosis in France
- Atypical Periocular Dermatophytosis Caused by Trichophyton mentagrophytes Species Complex Misdiagnosed as Refractory Bacterial and Viral Infection
- The Effect of Oral Isotretinoin on Quality of Life in Patients With Acne Vulgaris: A Systematic Review and Meta-Analysis of Patient-Reported Outcomes
BibTeX
@article{yadav2026safety,
title = {{A safety and efficacy of oral itraconazole and oral itraconazole with isotretinoin in chronic and recurrent dermatophytosis- A randomized trial}},
author = {Nidhi Yadav and Rachna Verma and Rupinder Kaur and Usha Chhillar},
journal = {Asian Journal of Medical Sciences},
year = {2026},
month = nov,
doi = {10.71152/ajms.v17i11.5561},
url = {https://doi.org/10.71152/ajms.v17i11.5561},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - A safety and efficacy of oral itraconazole and oral itraconazole with isotretinoin in chronic and recurrent dermatophytosis- A randomized trial
AU - Nidhi Yadav
AU - Rachna Verma
AU - Rupinder Kaur
AU - Usha Chhillar
PY - 2026
DA - 2026/11/01
JO - Asian Journal of Medical Sciences
DO - 10.71152/ajms.v17i11.5561
UR - https://doi.org/10.71152/ajms.v17i11.5561
AB - Background: A significant rise in chronic and recalcitrant dermatophytosis unresponsive to standard antifungals at recommended doses and durations has been observed in recent years. This growing resistance underscores the need for newer adjuvant therapies, such as combining isotretinoin with itraconazole. Aims and Objectives: The aim of the study was to evaluate the safety and efficacy of oral itraconazole versus itraconazole with isotretinoin in chronic and recurrent dermatophytosis. Materials and Methods: Patients were randomized into two groups. Group A received itraconazole 200 mg orally daily for 4 weeks, while Group B received itraconazole plus isotretinoin 20 mg daily. Results: Of 70 patients enrolled, 64 (33 in Group A, 31 in Group B) completed the study. Group B demonstrated a significant reduction in Clinical Assessment Score at 4 weeks (P=0.007). Excellent (>80%) improvement in Global Assessment Index was achieved in 58% of Group A and 78% of Group B (P=0.011). Patient satisfaction was higher in Group B (83.8%) compared to Group A (57.5%) (P=0.03). Mycological cure on potassium hydroxide was obtained in 63.6% of Group A and 90.3% of Group B (P=0.012). Relapse rates at 2month follow up were significantly lower in Group B (P=0.014). Conclusion: The combination of oral isotretinoin and itraconazole was more effective than itraconazole monotherapy in achieving clinical and mycological cure, improving patient satisfaction, and reducing relapse in chronic, recurrent dermatophytosis.
SN - 2467-9100
SN - 2091-0576
ER -